Friday, November 13, 2026

Apollo Raised NOVO BANCO Bid But Fosum and Anbang Offers Are Still in the Race

Banco de Portugal confirmed Apollo Global Management raised its bid for Novo Banco in August 2015, while Chinese competitors Fosun and Anbang held their offers. The sale of Portugal's third-largest bank carried major implications for the country's banking resolution fund.

LM Salvado
LM Salvado

August 12, 2015

Novo Banco - Image Credit João Ramos

Banco de Portugal, the institution overseeing the sale of Novo Banco, confirmed in August 2015 that American private equity firm Apollo Global Management increased its bid for the troubled Portuguese lender. The two other contenders—Chinese conglomerates Fosun International and Anbang Insurance Group—did not raise their offers.

Novo Banco, Portugal's third-largest bank by assets, was created in August 2014 as a "good bank" successor to Banco Espírito Santo following its collapse. The state-backed rescue isolated toxic assets linked to the founding Espírito Santo family's debts, with the resolution funded by Portugal's banking sector.

While Apollo improved its offer, sources familiar with the negotiations indicated that Anbang's bid remained the highest among the three finalists. The exact terms of each proposal were not disclosed by the regulator.

Banco de Portugal stated it expected to reach a final decision in the coming weeks. The outcome carried significant implications for Portugal's financial system: any shortfall from the sale would be borne by the Portuguese banks' resolution fund, potentially requiring additional contributions from the country's banking sector.

Editor's note: This article was originally published in August 2015. The Novo Banco sale process ultimately concluded in October 2017, when Lone Star Funds acquired a 75% stake in the bank.

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com